0QF Stock Overview
A biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally.
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 1/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Moderna, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$58.88 |
| 52 Week High | US$155.50 |
| 52 Week Low | US$56.81 |
| Beta | 1.67 |
| 11 Month Change | -16.72% |
| 3 Month Change | -47.12% |
| 1 Year Change | -39.86% |
| 33 Year Change | -79.90% |
| 5 Year Change | 329.78% |
| Change since IPO | 273.84% |
Recent News & Updates
Recent updates
Shareholder Returns
| 0QF | DE Biotechs | DE Market | |
|---|---|---|---|
| 7D | -0.3% | 2.6% | 4.5% |
| 1Y | -39.9% | -16.4% | 13.4% |
Return vs Industry: 0QF underperformed the German Biotechs industry which returned -16.4% over the past year.
Return vs Market: 0QF underperformed the German Market which returned 13.4% over the past year.
Price Volatility
| 0QF volatility | |
|---|---|
| 0QF Average Weekly Movement | 8.9% |
| Biotechs Industry Average Movement | 6.3% |
| Market Average Movement | 5.0% |
| 10% most volatile stocks in DE Market | 11.8% |
| 10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: 0QF's share price has been volatile over the past 3 months.
Volatility Over Time: 0QF's weekly volatility (9%) has been stable over the past year, but is still higher than 75% of German stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2010 | 5,600 | Stephane Bancel | www.modernatx.com |
Moderna, Inc., a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines. The company also offers systemic secreted and cell surface therapeutics; cancer vaccines, such as personalized cancer, KRAS, and checkpoint vaccines; intratumoral immuno-oncology products; rare disease intracellular therapeutics; and inhaled pulmonary therapeutics.
Moderna, Inc. Fundamentals Summary
| 0QF fundamental statistics | |
|---|---|
| Market cap | €22.64b |
| Earnings (TTM) | -€5.25b |
| Revenue (TTM) | €4.52b |
5.0x
P/S Ratio-4.3x
P/E RatioIs 0QF overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 0QF income statement (TTM) | |
|---|---|
| Revenue | US$5.05b |
| Cost of Revenue | US$8.23b |
| Gross Profit | -US$3.18b |
| Other Expenses | US$2.69b |
| Earnings | -US$5.87b |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -15.26 |
| Gross Margin | -62.99% |
| Net Profit Margin | -116.18% |
| Debt/Equity Ratio | 0% |
How did 0QF perform over the long term?
See historical performance and comparison